Role of CCR1 in loading-dose atorvastatin in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Objective To investigate the role of CC chemokine receptor 1(CCR1) in the treatment of loading-dose atorvastatin in the patients with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention(PCI).Methods A total of 120 ACS patients was equally randomized into groups of A and B.Group A received atorvastatin 80 mg before 30 minutes of PCI,40 mg/d after PCI,and then 20 mg/d after 30 days.Group B received atorvastatin 20 mg/d before and after PCI.PCI associated myocardial infarction(MI) and major adverse cardiac events(MACE) in 30 days after PCI were recorded.The plasma concentration of CCR1 was detected by ELISA method before PCI,at 24 hours,1 week,2 weeks and 4 weeks after PCI,respectively.Results The incidence rates of PCI-associated MI and MACE in 30 days after PCI were significantly lower in group A than those in group B(5.00% vs.23.33% and 3.33% vs.15.00%)(P0.01 and P0.05).Compared with before,plasma concentration of CCR1 in group B increased at 24 hours after PCI(P0.01),which thereafter was decreased in both groups and was lower in group A than that in group B(P0.01).Conclusion Loading-dose atorvastatin used before 30 minutes of PCI could significantly decrease the incidence of PCI-associated MI and MACE in 30 days after PCI by reducing serum CCR1.